Livia Stanger and Colleagues Link CS014 to in Vivo Thrombosis
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis
CS014, a novel HDAC inhibitor, prevents blood clots as effectively as valproic acid but without hepatotoxic metabolites, offering safer antithrombotic therapy without increasing bleeding risk.”
Read the full article here.
Article: Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis
Authors: Livia Stanger, Pooja Yalavarthi, Reheman Adili, Devin Gilmore, Timothy Hoang, Avery Campbell, Paul Krenik, David Gustafsson, Jan Fryklund, Tomas Fex, Nicholas Oakes, Jonas Faijerson Säljö, Björn Dahlöf, Joan Beckman, Michael Holinstat
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 29, 2026, 15:50Sweta Agrawal: Expanding Care for PNH Patients in Nepal
-
Jun 29, 2026, 15:17Heghine Khachatryan: Hemostasis at the Crossroads of Thrombosis and Bleeding
-
Jun 29, 2026, 15:07Tomaz Crochemore: From Bleeding to Thrombosis – The Era of Precision Hemostatic Medicine Has Arrived
-
Jun 29, 2026, 14:51Pete Stibbs: Building a Successful Venous Thrombectomy Practice
-
Jun 29, 2026, 14:30Bruno Pougault: Pregnancy and Thrombosis – Balancing Evolutionary Protection Against Clinical Risk
-
Jun 29, 2026, 13:32Omid Seidizadeh: The Full VWD Session from EHA 2026 Is Now Available to Watch
-
Jun 29, 2026, 13:22Cheryl Carcel: Make The Stroke Research More Inclusive for Women, Take The Survey
-
Jun 29, 2026, 13:18Bianca Rocca: New Expert Opinion On the Evolving Debate on Factor XI as a Therapeutic Target
-
Jun 29, 2026, 13:06Francisco Chacón-Lozsán: Intermittent Hemodialysis in the ICU Should not be Monitored Only by ‘Session Completed’